POINT RICHMOND, Calif., May 8, 2013 /PRNewswire/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT), a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic ...

Point Richmond, Calif., May 1, 2013 /PRNewswire/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT), a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs ...

New York, NY - (NISMAGAZINE) - 5/07/2013- Transcept Pharmaceuticals Inc (NASDAQ:TSPT) fell 7.43% at $3.86 after trading 76,637 shares.

Transcept Pharmaceuticals, Inc., formerly Novacea, Inc., is a specialty pharmaceutical company focused on the development and commercialization of products that address important therapeutic needs in neuroscience.

Transcept Pharmaceuticals Incorporated has a one year low of $3.89 and a one year high of $11.38. The stock's 50-day moving average is currently $4.. The company's market cap is $60.4 million. Transcept Pharmaceuticals, Inc., formerly Novacea, Inc., is ...

Five equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the company's stock.

NASDAQ 20 Most Declined Stocks Today - Himax Tech, Geospace Tech, Synacor Inc, Transcept Pharma, AVEO Pharma - HIMX, GEOS, TSPT, AVEO, SYNC, VISN, GRPN, LNCO, DRWI, ARLP.

Purdue Pharmaceuticals LP will shelve 90 contract sales people it used to exclusively hawk the Transcept Pharmaceuticals Inc.-developed middle-of-the-night sleep drug Intermezzo. Intermezzo will continue to be sold through Purdue's roughly 525-person ...

Currently, companies like Vertex Pharmaceuticals Inc. ( VRTX ), Cleveland BioLabs, Inc. ( CBLI ) and Transcept Pharmaceuticals, Inc. ( TSPT ) look more attractive in the pharma space. All three stocks carry a Zacks Rank #1 (Strong Buy). CLEVELAND BIOLB ...

Pfizer Inc. (NYSE:PFE) fell -4.47% to settle at $29.07, Transcept Pharmaceuticals Inc (NASDAQ:TSPT) moved up +0.51% to end at $3.96 while Forest Laboratories, Inc. (NYSE:FRX) jumped +0.54% to finish at $37.41 on Tuesday.